Key Takeaways
- ImmunityBio received an FDA warning letter regarding a television commercial and podcast containing false promotional statements about bladder cancer treatment ANKTIVA
- Marketing materials incorrectly implied ANKTIVA could address all cancer types — approval is limited to a narrow bladder cancer indication used with BCG therapy
- The FDA specifically named CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong in connection with the violations
- This represents ImmunityBio’s third regulatory communication regarding promotional misconduct, after previous letters in September 2025 and January 2026
- ImmunityBio must submit a corrective action plan within 15 working days or potentially face legal enforcement
Shares of ImmunityBio tumbled significantly on Tuesday after federal regulators issued a warning letter criticizing the company for broadcasting false and misleading information about its cancer drug ANKTIVA in both television advertising and podcast content.
The FDA’s Office of Prescription Drug Promotion delivered the warning letter to ImmunityBio in response to a television advertisement and a podcast episode entitled “Is the FDA BLOCKING Life Saving Cancer Treatments?” Regulators concluded that both promotional pieces breached federal regulations.
The fundamental problem centered on overstating the drug’s approved applications. ANKTIVA has received authorization for a highly specific indication: treating adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, either with or without papillary tumors, delivered via intravesical administration in combination with BCG therapy.
The marketing content dramatically exceeded these boundaries. Claims made in the materials indicated ANKTIVA could “treat all cancers,” serve as a preventive measure for individuals exposed to radiation, and function effectively as a standalone single-injection therapy. The FDA stated that none of these assertions are backed by clinical evidence or have received regulatory approval.
Both CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong were featured in the promotional content and were explicitly identified in the FDA’s enforcement letter.
According to the FDA, these materials constituted misbranding of ANKTIVA and rendered the product’s distribution in violation of the Federal Food, Drug, and Cosmetic Act.
Pattern of Regulatory Concerns
This warning represents a repeat offense for ImmunityBio. The agency had previously dispatched untitled letters in September 2025 and January 2026 to Altor BioScience, an ImmunityBio subsidiary, addressing comparable promotional violations.
Tuesday’s correspondence represents the third regulatory action — and the most severe to date. FDA warning letters carry substantially greater regulatory significance than untitled letters and demonstrate the agency’s growing concern about ongoing compliance failures.
The FDA additionally criticized ImmunityBio for inadequately presenting risk information within the promotional materials and for excluding critical details about the drug’s authorized indication.
The podcast episode also violated submission requirements, as it was not provided to the FDA at the time of initial publication — a separate regulatory obligation the company neglected.
Stock Price Impact
IBRX stock declined between 15% and 21% on Tuesday, with some trading platforms recording intraday losses approaching 21% during morning session activity.
ImmunityBio must now deliver a written response to the FDA within 15 working days detailing a comprehensive plan to address and remedy the identified violations.
The company is additionally mandated to deploy corrective communications specifically targeting the audiences who were exposed to the misleading promotional materials.
The FDA cautioned that insufficient corrective action could trigger formal legal proceedings against the company.
